Walter Jonat

Walter Jonat

Auto-generated profile, based on publicly available information

Walter Jonat

Klinik für Gynäkologie und Geburtshilfe, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2013 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
WJW. Jonat
W. Jonat
TBT. Bachelot
T. Bachelot
TRT. Ruhstaller
T. Ruhstaller
IKI. Kuss
I. Kuss
URU. Reimann
U. Reimann
JRJ. F. R. Robertson
J. F. R. Robertson
The progesterone-receptor (PR) antagonists onapristone (type I) and mifepristone (type II) showed modest activity in hormone-receptor-positive breast cancer; however, onapristone in particular was associated with hepatotoxicity. Lonaprisan is a novel, type III PR antagonist that was well tolerated in phase I studies. This randomized, open-label, phase II study evaluated the efficacy and tolerability of lonaprisan as second-line endocrine therapy in postmenopausal women with stage IV, PR-positive, HER2-negative, metastatic breast cancer. Patients received once-daily lonaprisan 25 mg (n = 34) or 100 mg (n = 34). The primary objective was not met (≥35% clinical benefit rate: complete/partial responses at any time until month 6 or stable disease [SD] for ≥6 months from start of treatment). There were no complete/partial responses. In the 25 mg and 100 mg groups, 6 of 29 patients (21%) and 2 of 29 patients (7%), respectively, had SD ≥6 months. Overall, 61 of 68 patients (90%) had ≥1 adverse event (AE), the most frequent (≥10% overall) being fatigue, hot flush, dyspnoea, nausea, asthenia, headache, constipation, vomiting, and decreased appetite; 33 patients had serious AEs. Lonaprisan showed limited efficacy as second-line endocrine therapy in postmenopausal women with PR-positive metastatic breast cancer.

1 October 2015
Verified
Journal Article
Closed access
TSThorsten Schmidt
Thorsten Schmidt
BWBurkhard Weisser
Burkhard Weisser
JDJuliane Dürkop
Juliane Dürkop
WJWalter Jonat
Walter Jonat
MMMarion Van Mackelenbergh
Marion Van Mackelenbergh
CMChristoph Mundhenke
Christoph Mundhenke

6 September 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AWAntonia Wenners
Antonia Wenners
JGJana Grambach
Jana Grambach
JKJuliane Koss
Juliane Koss
NMNicolai Maass
Nicolai Maass
WJWalter Jonat
Walter Jonat
CMChristoph Mundhenke
Christoph Mundhenke
The numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy. Fifty-one premenopausal women (28–46 years) with primary breast cancer were included in the trial. All of them received anthracycline-based chemotherapy (n = 18), or combinations with taxanes (n = 30), or anthracycline-free chemotherapy (n = 3). Changes in hormone levels (LH, FSH, E2 and Anti-Müllerian hormone (AMH)), antral follicle count (AFC), and amenorrhea were determined before (V1), and 6, 12 and 24 months after the initiation of chemotherapy (V2-V4). Quality of life parameters were evaluated. The additional impact of parity, BMI, and smoking on ovarian reserve was also assessed. AFC and AMH fell very markedly after chemotherapy and did not return to pre-treatment levels until V4. A significant positive correlation was noted in AFC before and 1 year after chemotherapy. AMH levels at V2-V4 were significantly correlated with those registered at V1. AFC and AMH were negatively correlated with age. Continued smoking had a significant detrimental effect on AFC after 24 months. LH and FSH levels increased between V1 and V2 and fell at V3 and V4, but stayed above pre-chemotherapy values. Two years after the start of chemotherapy 31/51 patients were amenorrhoic while 17 resumed their menstrual cycle; this was not influenced by the type of chemotherapy or age. Non-smokers were 13 times more likely to resume their menstruation than smokers. Quality of life (QL) was significantly lower 6 months after the initiation of chemotherapy. QL at one and 2 years after chemotherapy did not differ significantly from pre-chemotherapy scores. Our study contributes to a better understanding and prediction of ovarian reserve in young early breast cancer patients undergoing chemotherapy. The data suggest that personal counseling in regard of the preservation of fertility should be offered especially to patients of a higher age, with low AMH levels or low follicle counts. Patients should be advised to stop smoking in order to enhance the likelihood of preserving their fertility.

1 June 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
IAIbrahim Alkatout
Ibrahim Alkatout
CSChristiane Stuhlmann-Laeisz
Christiane Stuhlmann-Laeisz
LMLiselotte Mettler
Liselotte Mettler
WJWalter Jonat
Walter Jonat
TSThoralf Schollmeyer
Thoralf Schollmeyer

1 March 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
IAIbrahim Alkatout
Ibrahim Alkatout
BBBernd Bojahr
Bernd Bojahr
LDLinda Dittmann
Linda Dittmann
VWViktoria Warneke
Viktoria Warneke
LMLiselotte Mettler
Liselotte Mettler
TSThoralf Schollmeyer
Thoralf Schollmeyer

1 August 2012
Verified
Journal Article
Closed access
TSThorsten Schmidt
Thorsten Schmidt
BWBurkhard Weisser
Burkhard Weisser
WJWalter Jonat
Walter Jonat
FBFreerk Theeagnus Baumann
Freerk Theeagnus Baumann
CMChristoph Mundhenke
Christoph Mundhenke